Liposem2 mg

Liposem is a dual PPAR-alpha/gamma agonist indicated for the following uses:

Established/Approved Use

• Diabetic dyslipidemia and hypertriglyceridemia in patients with type 2 diabetes mellitus whose lipid abnormalities are not adequately controlled by statin therapy alone. Liposem is used as an add-on to statin therapy, not as a substitute for standard first-line statin treatment of dyslipidemia.

Emerging / Regionally-Approved Use

• In some approved markets (notably the Indian subcontinent), Liposem is also used for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), based on evidence of improvement in liver fat content and liver enzymes. This use has more limited global regulatory approval and a smaller evidence base compared to long-established antidiabetic and lipid-lowering drug classes, and treatment decisions should be individualized by a physician.

Liposem is a relatively newer, regionally-approved agent; it should be used within its approved indications and under physician supervision.

Each film-coated tablet contains Saroglitazar Magnesium equivalent to 2 mg or 4 mg of saroglitazar, along with pharmaceutically approved excipients.

Liposem is a novel dual peroxisome proliferator-activated receptor (PPAR) agonist, predominantly acting on PPAR-alpha with moderate PPAR-gamma agonistic activity. It was developed to address diabetic dyslipidemia, a combination of high triglycerides and insulin resistance commonly seen in type 2 diabetes. Liposem is approved and marketed in select markets, including the Indian subcontinent, and is available in Bangladesh as an oral tablet.

Saroglitazar Magnesium acts as a dual agonist of peroxisome proliferator-activated receptors (PPAR):

• PPAR-alpha activation (predominant effect) increases hepatic fatty acid oxidation, reduces triglyceride synthesis, and activates lipoprotein lipase, lowering triglycerides, LDL cholesterol, VLDL cholesterol, and non-HDL cholesterol while raising HDL cholesterol.
• PPAR-gamma activation (moderate effect) improves insulin sensitivity and glucose utilization by regulating insulin-responsive genes involved in carbohydrate and lipid metabolism, thereby improving glycemic control markers.

In vitro studies indicate Saroglitazar Magnesium does not significantly inhibit or induce major cytochrome P450 enzymes, suggesting a relatively low potential for clinically significant drug-drug interactions via this pathway.

Liposem tablets are taken orally, once daily, with or without food, swallowed whole with a glass of water. Do not crush or chew unless directed by a physician.

In vitro data suggest Liposem has a low potential for cytochrome P450-mediated drug interactions. However, clinically relevant considerations include:

• Statins and fibrates: Liposem is frequently co-administered with statins for diabetic dyslipidemia; combining PPAR agonists with statins or fibrates may theoretically increase the risk of myopathy, so patients should be monitored for unexplained muscle pain, tenderness, or weakness.
• Other antidiabetic agents: As Liposem can improve glycemic control, concurrent use with insulin or other glucose-lowering drugs may require monitoring for hypoglycemia and dose adjustment.

Inform the treating physician of all other medicines being taken before starting Liposem.

The most commonly reported adverse effects of Liposem (occurring in more than 2% of patients) include:

• Gastritis
• Asthenia (weakness/fatigue)
• Pyrexia (fever)

Other reported effects include mild elevations in liver enzymes, myalgia, and increases in serum creatinine. Most adverse events have been mild to moderate and generally did not require discontinuation. See Precautions and Warnings for fluid retention/edema and hepatic monitoring guidance.

Liposem is classified under pregnancy category C. Adequate and well-controlled studies in pregnant women are not available. Liposem should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; consult a physician before use.

It is not known whether Liposem is excreted in human breast milk. Because many drugs are excreted in breast milk, caution should be exercised and a physician consulted before use of Liposem in breastfeeding mothers; if necessary, an alternative feeding method or discontinuation of the drug should be considered based on medical advice.

Use Liposem with caution in the following situations:

• Hepatic function: Baseline and periodic liver function testing is advisable, as with other PPAR-agonist class drugs; use caution in patients with abnormal liver function or active liver disease.
• Fluid retention/edema: PPAR agonists as a class can cause fluid retention and weight gain; use with caution in patients with heart failure or a predisposition to edema, and monitor accordingly.
• Renal function: Periodic monitoring of renal function and serum creatinine is recommended; use caution in patients with renal impairment.
• Gallbladder-related events: Gallbladder-related adverse events have been reported with some PPAR agonists; monitor for symptoms such as abdominal pain, especially in the right upper quadrant.
• Myopathy risk: Use caution when combining with statins or fibrates (see Drug Interactions); monitor for unexplained muscle symptoms.
• Liposem is not a substitute for standard first-line statin therapy in dyslipidemia and should be used as directed for its specific approved indication(s), in combination with existing diabetes or lipid-lowering therapy where appropriate.
• Liposem is a relatively newer, regionally-approved agent (notably in the Indian subcontinent) with a more limited global regulatory approval history and evidence base compared to long-established antidiabetic and lipid-lowering drug classes; use should follow current local prescribing guidance.

No cases of overdose with Liposem have been reported in clinical use. In the event of a suspected overdose, seek immediate medical attention or contact emergency services/poison control. Management should consist of general supportive care, including monitoring of vital signs and symptomatic treatment as directed by a physician.

Store below 25°C in a dry place, protected from light and moisture. Keep out of reach of children.

Hepatic impairment: Use Liposem with caution; periodic liver function monitoring is advised (see Precautions and Warnings).

Renal impairment: Use Liposem with caution and monitor renal function; dose adjustment recommendations are not well established for severe renal impairment, so specific product labeling should be verified.

Elderly: Use Liposem with caution in elderly patients, considering the likelihood of comorbidities such as cardiac or hepatic/renal disease.

Pediatric patients: Safety and efficacy of Liposem have not been established in patients under 18 years of age; use in this group is not recommended.

The duration of treatment with Liposem is individualized by the treating physician based on lipid profile, glycemic control, and liver-related parameters (where relevant), with periodic reassessment. Do not stop or extend treatment without medical advice.

Saroglitazar Magnesium belongs to the glitazar class - a dual PPAR-alpha/gamma (peroxisome proliferator-activated receptor) agonist.

Saroglitazar Magnesium acts as a dual PPAR-alpha/PPAR-gamma agonist: PPAR-alpha activation lowers triglycerides and improves the overall lipid profile, while PPAR-gamma activation improves insulin sensitivity and glycemic control.

C

Safety and efficacy of Liposem have not been established in pediatric patients (under 18 years of age). Its use is therefore not recommended in this age group.